\_/ Yesterday’s breaking news came as a total surprise as two of the pharma sector giants were put under scrutiny. Publications from Cochrane Collaboration and British Medical Journal claimed two widely popular drugs (Roche’s Tamiflu and Glaxosmithkline’s Relenza) of these companies were in fact not effective against fighting influenza. Needless to say the latest events also raised questions about drug trials once again.
Below, you can find links of different angles covering the story and the source of claims along with a list of series of events escalating toward the allegations regarding the evidence aginst these two products.
‘Tamiflu Is No Better Than Tylenol At Fighting Flu’
“Tamiflu and Relenza, the world’s front-line defences against influenza, are only as effective as paracetamolor acetaminophen, the active ingredient in Tylenol, at fighting the disease. Analysis of clinical trial data released
By Paul Rodgers
The Tamiflu Timeline
“A timeline of key links and articles, in response to the drugs company Roche not publishing all clinical trial data on Tamiflu and more relating to the #AllTrials campaign.”
By Milward Holy
Neuraminidase Inhibitors For Preventing And Treating Influenza In Healthy Adults And Children
Source: The Cochrane Library
The Tamiflu Trials
Source: British Medical Journal
Tamiflu: Millions wasted on flu drug, claims major report
“Hundreds of millions of pounds may have been wasted on a drug for flu that works no better than paracetamol, a landmark analysis has said.
The UK has spent £473m on Tamiflu, which is stockpiled by governments globally to prepare for flu pandemics.
The Cochrane Collaboration claimed the drug did not prevent the spread of flu or reduce dangerous complications, and only slightly helped symptoms.
The manufacturers Roche and other experts say the analysis is flawed.
The antiviral drug Tamiflu was stockpiled from 2006 in the UK when some agencies were predicting that a pandemic of bird flu could kill up to 750,000 people in Britain. Similar decisions were made in other countries.
The drug was widely prescribed during the swine flu outbreak in 2009.
Drug companies do not publish all their research data. This report is the result of a colossal fight for the previously hidden data into the effectiveness and side-effects of Tamiflu…”
By James Gallagher